Biodefense Market
Biodefense Demand Grows as Current Technologies are Expanded to Benefit Society. FMI Tracks Demand across 30+ Countries.
Biodefense Market By Product & Region | Forecast 2023 to 2033
Biodefense Market Outlook
The global biodefense market size was valued at US$ 16.31 billion in the year 2023 and is estimated to reach a revised size of US$ 32.99 billion by 2033. This market is projected to expand at a CAGR of 7.3% during the analysis period. Increasing demand for vaccines, drugs, and medical devices creates opportunities for companies to expand their businesses and penetrate new markets.
Biological terrorism involves the deliberate release of viruses, bacteria, and other harmful germs capable of spreading epidemics and causing death. It has a detrimental impact on the economy because of the damage it causes to human health and the drain on human resources. Therefore, developed countries undertake a variety of efforts, as well as preventive measures, to strengthen their defense against these attacks.
Various countries maintain a constant supply of vaccines and biothreat detection technology to ensure the safety of their citizens. Government initiatives like this may help to accelerate the growth of the biodefense industry. It is possible to use biological toxins or infectious agents with malicious intentions, such as killing or infecting humans, animals, or the environment or even provoking biological warfare. In addition to living organisms such as bacteria, viruses, fungi, and toxins, several agents are used in bioterrorism.
By deliberately infecting and killing people, these agents can be used to cause social and economic turmoil. As a result of government initiatives, and increased government attention and funding towards biodefense strategies, the biodefense market is fueled by various factors. For example, the Department of Defense is modernizing its approach to develop medical countermeasures to protect warfighters from novel biological agents.
In the years to come, the scope of the biodefense market may be further expanded by increasing private investment. This is due to the occurrence of different viruses such as the flu, the Ebola virus, and the Zika virus.
Some technological advancements have been made in genetic engineering and biotechnology in the past few years. These advancements have enabled innovative approaches to combat these deadly, naturally occurring viruses that can be redesigned to cause additional harm. Moreover, these organisms are readily available, making biodefense an imperative aspect of countries around the world. The use of various biological agents, such as botulism, anthrax, and chemical and nuclear agents, has contributed to severe destruction as a result of bioterrorism.
Attributes |
Details |
Biodefense Market Value (2023) |
US$ 16.31 billion |
Biodefense Market Expected Value (2033) |
US$ 32.99 billion |
Biodefense Market Projected CAGR (2023 to 2033) |
7.3% |
Let us know your requirement to get
100% FREE customization
Global Biodefense Market Historical Analysis (2017 to 2022) Vs. Forecast Outlook (2023 to 2033)
The global biodefense market expanded at 8.1% CAGR over the past 10 years. The market is anticipated to expand at a CAGR of close to 7.3% over the forthcoming decade.
Biodefense markets were positively impacted by the pandemic. As a result of the pandemic, numerous government and non-governmental agencies were required to coordinate their responses nationwide, as catastrophic biological events can result in significant human and economic losses. Since the pandemic promises huge potential for investment and income redistribution, there are many reasons to believe it is an intentional act of bioterrorism.
- Short Term (2023 to 2026): As the market grows, it may provide new opportunities for companies developing and producing vaccines, diagnostics, and therapeutic products for the prevention and treatment of infectious diseases.
- Medium Term (2026 to 2029): The market is driven by factors such as increasing government funding for research and development, growing concern over the threat of pandemics and bioterrorism, and advancements in biotechnology.
- Long Term (2029 to 2033): The prominent advancement of biotechnology is leading to the development of new and more effective biodefense products, such as vaccines and diagnostic tests, providing opportunities for companies in the biodefense market.
Historical CAGR (2016 to 2022) |
8.1% |
Historical Market Value (2022) |
US$ 15.20 billion |
Forecast CAGR |
7.3% |
Comparative Analysis of Adjacent Biodefense Markets
Biodefense Market:
Differentiating Aspects |
Biodefense Market |
CAGR (2023 to 2033) |
7.3% |
Market Valuation in 2023 |
US$ 16.31 billion |
Projected Market Value in 2033 |
US$ 32.99 billion |
Growth Factors |
Rising investment in research and development for biodefense. |
Opportunities |
Growing demand for vaccines due to the emergence of new diseases. |
Key Trends |
The rise in infectious diseases and increase in demand for services in the biodefense market |
Forensic Technology Market:
Differentiating Aspects |
Forensic Technology Market |
CAGR (2023 to 2033) |
10.5% |
Market Valuation in 2023 |
US$ 5.25 billion |
Projected Market Value in 2033 |
US$ 14.25 billion |
Growth Factors |
Development of advanced technologies such as DNA analysis etc. |
Opportunities |
The expansion of forensic services creates opportunities for companies to expand their businesses. |
Key Trends |
Rise in crime rates and government initiatives to improve criminal investigations. |
Biosensors Market:
Differentiating Aspects |
Biosensors Market |
CAGR (2023 to 2033) |
8.1% |
Market Valuation in 2023 |
US$ 29.1 billion |
Projected Market Value in 2033 |
US$ 63.40 billion |
Growth Factors |
Increase in demand for quick and convenient medical testing. |
Opportunities |
Increasing demand for remote patient monitoring systems. |
Key Trends |
Development of new technologies like miniaturization, integration with wearables, and improved sensitivity. |
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFactors Driving the Biodefense Market
- Rise in Technological Advancements
Due to the rise of bioterrorism, prominent industry players have incorporated advances in biothreat detection systems. These advances aid in the identification of bacteria and viruses that may be beneficial to market growth during the analysis period. As a result, technological breakthroughs can have a beneficial influence on market growth. To secure the security and safety of the population, technologically sophisticated biothreat detection technologies are necessary, which can help boost the market's growth.
To detect pathogens in nanotechnology, forensics, and biodefense-related drug development, innovative technologies, including gene chips, are widely used. As a means of improving agricultural yields, synthetic biology is also contributing to market growth, as it improves agricultural yields.
- Increase in Investments by Government for Defense Expenditure
It is one of the key factors driving the growth of the market that the threat of terrorism is growing along with an ever-increasing level of tension between nations. It is also contributing to biodefense market growth that governments across several nations are increasing their defense spending to improve both internal and external security.
For example, the United States Department of Defense (DoD) spent US$ 718 billion in FY 2021, with the large category being operation and maintenance at US$ 286 billion. Furthermore, government agencies are developing medical countermeasures for chemical, biological, nuclear, and radiological threats to minimize the adverse effects of these attacks.
- The Rise in Demand for Vaccines
The development of novel vaccine technologies, such as vector technology, is expected to drive the growth of the biodefense market as they can provide rapid protection against pathogen attacks. In recent years, vaccines have been developed that can combat a wide variety of bioterrorism chemicals and can induce long-lasting immune responses.
Several countries are experiencing a surge in Ebola and Zika infections, resulting in a race to develop vaccines. The government spends a lot of money on vaccine research and development to make sure it is prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense market have a huge opportunity to expand since governments are always looking for ways to prevent bioterrorism.
Category-wise Insights
Product Insights: The Anthrax Segment is expected to be the significant Contributor to the Market
In terms of products, the market is segmented into anthrax, smallpox, botulism, radiation/nuclear, and others. The anthrax segment held a prominent market share of 28.1% in 2023. Many factors contribute to the growth of the anthrax product segment. Some of these factors include the increase in anthrax outbreaks in humans, favorable government initiatives, and collaboration in research and development in the studied fields.
In July 2022, as reported by the media, 15 cases of cutaneous anthrax were linked to an anthrax outbreak in cattle in Sisak-Moslavina County following heavy rain, according to the European Centre for Disease Prevention and Control (ECDC) Communicable Disease Threat Report. Moreover, in July 2022, the Croatian Ministry of Agriculture issued an order containing measures to prevent the outbreak and spread of anthrax in the affected area. These measures include closures of affected areas, vaccinations of animals, and additional human prevention measures.
One of the most likely potential weapons used in a bioterrorist attack is Bacillus anthracis, a gram-positive bacterium that causes anthrax. Those spores are preferred because they can be easily released into the environment by adding them to food, water, powders, and sprays. The bacterium can persist in the environment for a long time and is easily found in nature (soil, plants, or water). As anthrax bacteria can be easily transmitted from one person to another, NCBI categorizes it as a tier-1 biological agent, which has the potential to cause a massive public health disaster.
In the field of countermeasures, anthrax remains a key focus. It has received a significant amount of funding for vaccine development. Many companies have developed anthrax vaccines, including Bioshield, which has received over US$ 50 billion in funding since the September 11 attacks.
In recent years, many countries have seen a rise in infection cases caused by the Zika virus and Ebola virus. This has prompted many companies to compete to develop vaccines for these viruses. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against two filoviruses, Ebola and Marburg's diseases, currently in phase 3 clinical trials and collaborating with the United States NIAID for the same.
Region Wise: North America Dominates the Market
In 2023, North America accounted for 79% of the biodefense market and is expected to exhibit a significant growth rate. As a result of federal funding, technological advancements, and growing awareness, this market is projected to expand significantly in the forecast period. Key players in this region make it easy for the biodefense market to grow in 2023. Increased research and development in the studies field, as well as increasing government initiatives, are the primary growth factors in this market.

A unified Market Research Subscription Platform, built for today's disparate research needs.
Regions Leading in Biodefense Market: Country-wise Analysis
The United States Biodefense Market Dominates North America Region
During the forthcoming years, the United States Biodefense Market is expected to dominate North America due to the growing importance of biodefense and increasing threats from harmful biological materials. Furthermore, the United States has well-established vaccine production facilities and is one of the region's most developed biodefense markets. Moreover, the United States government implements some initiatives that help them strengthen security against bioterrorism attacks. For example, the government plans a pandemic influenza program and a program to fight infectious diseases.
The regional market forecast may also be influenced by other factors, such as the growing adoption of technologically advanced products and the increasing awareness of biodefense among individuals.
A leadership structure and a comprehensive strategy were established in National Security Presidential Memorandum 14 (NSPM-14) to coordinate all biodefense efforts associated with the U.S. Government. The combination of the strategy and memorandum enabled the annual budget planning process to identify and connect gaps for the first time.
Why is Germany’s Biodefense Market Considered Lucrative within Europe?
In Germany, biodefense products and services are manufactured and sold to protect against biological threats such as infectious diseases and bioterrorism. It consists of a wide range of products and services, including vaccinations, diagnostic tests, protective equipment, and decontamination systems.
Germany is considered a leading player in the global biodefense market. This is because it has a strong presence of multinational corporations and government institutions involved in research and development, as well as the production and distribution of biodefense products. The government of Germany has also made significant investments in the biodefense sector, which has helped to spur growth and innovation in the market.
Overall, the biodefense market in Germany is expected to continue growing in the coming years. This is driven by factors such as increasing concerns about global pandemics, bioterrorism, and the growing threat of antimicrobial resistance.
What Makes China Biodefense Market Highly Attractive?
During the forecast period, China is expected to expand at the high rate of 8.8% due to surges in Research and development. Growing awareness of biodefense, as well as the threat of harmful biological materials that engender emergencies, can drive growth in the biodefense market.
A combination of this and a sophisticated healthcare infrastructure contributes to China's market position. In addition, China is vigorously expanding its research and development capabilities to meet future biological threats. After the United States, China spends the second highest percentage of its GDP on research and development. These factors are expected to boost China's biodefense industry.
Start-up Ecosystem
The biodefense market is home to several startups around the world. These startups are focused on developing innovative solutions to protect against biological threats, including infectious diseases and bioterrorism.
Some examples of Startups Operating in the Biodefense Market include:
- BioMimetix JV, LLC: a company based in Germany develops biometric solutions for identifying and tracking infectious diseases.
- BioDetectors: the United Kingdom-based startup that develops rapid diagnostic tests for the detection of biological threats.
- PathAI: a company that uses artificial intelligence to improve the accuracy of disease diagnosis.
- Tener Vaccines: Germany-based startup that focuses on the development of vaccines for the prevention of infectious diseases.
- Takeda Pharmaceuticals: Japan-based pharmaceutical company that develops and sells vaccines and treatments for infectious diseases.
- Biomatrica: the United States-based company that provides solutions for the preservation of biological samples for research and diagnostic purposes.
These startups are working on developing and commercializing cutting-edge technologies and products to address the challenges posed by biological threats. They play an influential role in driving innovation and growth in the biodefense market.
Competitive Landscape: Key Players Operating in the Market
In emerging and economically favorable regions, many of these players are notably collaborating with governments to gain bulk orders and boost sales. Many companies are partnering with each other to develop drugs so that they can introduce their products fast.
Key players operating in the Market:
- XOMA Corporation
- Altimmune Inc.
- Emergent Biosolutions Inc.
- Dynavax Technologies Corporation
- SIGA Technologies
- Elusys Therapeutics Inc
- Ichor Medical Systems
- Dynport Vaccine Company
- Cleveland Biolabs
- Bavarian Nordic
- Ology Bioservices
- Alnylam Pharmaceuticals Inc.
Recent Developments:
Key players are focusing on novel and innovative approaches for the development of new Biodefenses. The strategy of expansion, new product launches, and approvals, by key manufacturers, are crucial strategies for further strengthening the presence of market players and allowing them to stay ahead of the competition.
- Appili Therapeutics Inc. announced funding of over US$ 10 million in February 2022 to advance its biodefense vaccine candidate, ATI-1701, to prevent infection with Francisella tularensis. This funding is expected to boost the company's presence and boost growth in the biodefense market.
- It was reported that Emergent BioSolutions Inc. (NYSE: EBS) has received approval for the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) from the United States Food and Drug Administration (FDA).
- It was announced in May 2022 that Emergent BioSolutions Inc. had signed a definitive agreement with Chimerix, Inc. to acquire Chimerix's exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the United States Food and Drug Administration (FDA) to treat smallpox in all age groups.
- The privately held company Ichor Medical Systems, Inc., announced in March 2019 that it collaborated with AstraZeneca for the development and clinical assessment of plasmid DNA constructs (recombinant monoclonal antibodies). Aside from upfront and annual payments, Ichor may also be paid development milestones under the terms of the agreement.
- CEPI (the Coalition for Epidemic Preparedness Innovations) entered into a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc., in August 2018, to manufacture a vaccine against the Lassa virus. Through this collaboration, companies were able to expand their product portfolio.
Scope of Report
Attribute |
Details |
Forecast Period |
2023 to 2033 |
Historical Data Available for |
2018 to 2023 |
Market Analysis |
US$ million for Value and MT for Volume |
Key Regions Covered |
|
Key Countries Covered |
United States, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom, Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Türkiye |
Key Segments Covered |
|
Key Companies Profiled |
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing |
Available upon Request |
Biodefense Market Segmentation by Category
By Product:
- Anthrax
- Smallpox
- Botulism
- Radiation/Nuclear
By Region Outlook:
- North America
- Latin America
- Europe
- The Middle East and Africa
- East Asia
Frequently Asked Questions
How is the Biodefense Market expected to value in 2023?
In 2023, the biodefense market is expected to reach US$ 16.31 billion.
In which Regions does the Biodefense Market have the most Potential?
The biodefense market in North America has the most potential.
What is the value of the Global Biodefense Market?
By 2033, the global biodefense market is projected to reach US$ 32.99 billion.
How is the Global Biodefense Market Expected to expand in terms of CAGR rate over the Forecast Period?
The global market for biodefense is projected to expand at 7.3% CAGR.
Table of Content
1. Executive Summary | Biodefense Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Anthrax Biodefense 5.3.2. Botulism Biodefense 5.3.3. Smallpox Biodefense 5.3.4. Cholera Biodefense 5.3.5. Influenza Biodefense 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033 6.3.1. Hospitals and Clinics 6.3.2. Ambulatory Care Centres 6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Type 8.2.3. By End-User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Type 8.3.3. By End-User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Type 9.2.3. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By End-User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Type 10.2.3. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By End-User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Type 11.2.3. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By End-User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Type 12.2.3. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By End-User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Type 13.2.3. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By End-User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Type 14.2.3. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By End-User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Type 15.1.2.2. By End-User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Type 15.2.2.2. By End-User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Type 15.3.2.2. By End-User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Type 15.4.2.2. By End-User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Type 15.5.2.2. By End-User 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Type 15.6.2.2. By End-User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Type 15.7.2.2. By End-User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Type 15.8.2.2. By End-User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Type 15.9.2.2. By End-User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Type 15.10.2.2. By End-User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Type 15.11.2.2. By End-User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Type 15.12.2.2. By End-User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Type 15.13.2.2. By End-User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Type 15.14.2.2. By End-User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Type 15.15.2.2. By End-User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Type 15.16.2.2. By End-User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Type 15.17.2.2. By End-User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Type 15.18.2.2. By End-User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Type 15.19.2.2. By End-User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Type 15.20.2.2. By End-User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Type 15.21.2.2. By End-User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By End-User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. XOMA corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Altimmune Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Emergent Biosolutions Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Dynavax Technologies Corporation. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. SIGA Technologies. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Elusys Therapeutics Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Ichor Medical Systems. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Dynport Vaccine Company. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Cleveland Biolabs. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Bavarian Nordic. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Ology Bioservices. 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Alnylam Pharmaceuticals Inc 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by End-User, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End-User, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 13: Global Market Attractiveness by Type, 2023 to 2033 Figure 14: Global Market Attractiveness by End-User, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by End-User, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 28: North America Market Attractiveness by Type, 2023 to 2033 Figure 29: North America Market Attractiveness by End-User, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by End-User, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 44: Latin America Market Attractiveness by End-User, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by End-User, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 58: Europe Market Attractiveness by Type, 2023 to 2033 Figure 59: Europe Market Attractiveness by End-User, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by End-User, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Type, 2023 to 2033 Figure 74: South Asia Market Attractiveness by End-User, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by End-User, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Type, 2023 to 2033 Figure 89: East Asia Market Attractiveness by End-User, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Type, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by End-User, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Type, 2023 to 2033 Figure 104: Oceania Market Attractiveness by End-User, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 107: MEA Market Value (US$ Million) by End-User, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 113: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 114: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 115: MEA Market Value (US$ Million) Analysis by End-User, 2018 to 2033 Figure 116: MEA Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033 Figure 117: MEA Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033 Figure 118: MEA Market Attractiveness by Type, 2023 to 2033 Figure 119: MEA Market Attractiveness by End-User, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports